March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Improvement Of Corneal Staining By A Sirt1 Activator In A Mouse Model Of Dry Eye
Author Affiliations & Notes
  • Achim H. Krauss
    Ophthalmology,
    GlaxoSmithKline, King of Prussia, Pennsylvania
  • Francisco Amparo
    Schepens Eye Research Institute, Boston, Massachusetts
  • Andre Okanobo
    Schepens Eye Research Institute, Boston, Massachusetts
  • David C. Gale
    Ophthalmology,
    GlaxoSmithKline, King of Prussia, Pennsylvania
  • Thomas C. Wilde
    DMPK,
    GlaxoSmithKline, King of Prussia, Pennsylvania
  • Caroline Sychterz
    DMPK,
    GlaxoSmithKline, King of Prussia, Pennsylvania
  • Rachel Apfelbaum
    Product Development, GlaxoSmithKline, Collegeville, Pennsylvania
  • Pratik Saha
    Product Development, GlaxoSmithKline, Collegeville, Pennsylvania
  • Jennifer Cermak
    Sirtris a GSK Company, Cambridge, Massachusetts
  • Reza Dana
    Schepens Eye Research Institute, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Achim H. Krauss, GSK (E); Francisco Amparo, None; Andre Okanobo, None; David C. Gale, GSK (E); Thomas C. Wilde, GSK (E); Caroline Sychterz, GSK (E); Rachel Apfelbaum, GSK (E); Pratik Saha, GSK (E); Jennifer Cermak, Sirtris a GSK Company (E); Reza Dana, GSK (F)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2343. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Achim H. Krauss, Francisco Amparo, Andre Okanobo, David C. Gale, Thomas C. Wilde, Caroline Sychterz, Rachel Apfelbaum, Pratik Saha, Jennifer Cermak, Reza Dana; Improvement Of Corneal Staining By A Sirt1 Activator In A Mouse Model Of Dry Eye. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2343. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the effect of the SIRT1 activator SRT1460 on corneal epithelial staining in the desiccating stress model of dry eye.

Methods: : All studies were conducted after review by the GSK Institutional Animal Care and Use Committee and in accordance with the GSK Policy on the Care, Welfare and Treatment of Laboratory Animals. Female C57BL/6 mice were placed in a controlled environment chamber (CEC) for a total of 9 or 18 days to induce ocular surface dryness. Following 2 or 4 days in CEC topical treatment was initiated and continued for 7 or 14 days. SRT1460, dexamethasone or vehicle were administered twice daily to both eyes in a 3 µL volume. Corneal fluorescein staining (CFS) was assessed using the NEI grading scale. Ocular tissue exposure in cornea and conjunctiva tissues were determined following two single topical instillations (30 μL drop) of a 9 mg/mL formulation in Dutch-belted rabbits (doses were 24 hr apart, N=4 eyes per time point).

Results: : Within 48 hours of exposure to CEC corneal fluorescein staining increased as described previously (Barabino et al, IOVS 2005). Compared to the start of treatment on day 2, CFS on day 9 was reduced by topical treatment with dexamethasone and vehicle by 24 and 32%, respectively, whereas CFS was further increased in the untreated group by 48%. SRT1460 reduced CFS by 26 and 49% in the low and high-dose groups, respectively. The reduction for the high-dose group was significant compared to the low-dose group, vehicle, dexamethasone and no treatment. Following topical administration of SRT1460 in Dutch-belted rabbits, cornea levels were 13.6 ± 5.99 μg/gram tissue one hour post last dose and 5.91 ± 6.08 μg/gram tissue seventy-two hours post last dose. Bulbar conjunctiva levels at one and 72 hours post last dose were 7.50 ± 5.20 μg/gram tissue and 0.263 ± 0.315 μg/gram tissue, respectively.

Conclusions: : Topical treatment with the SIRT1 activator SRT1460 resulted in a significant improvement in corneal barrier function in a mouse model of dry eye. SIRT1 activators potentially represent a novel class for the treatment of dry eye disease.

Keywords: cornea: tears/tear film/dry eye • cornea: epithelium 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×